Email this article Glucose variability in pregnant women with newly diagnosed hyperglycemia
- Authors: Plekhanova M.A.1, Burumkulova F.F.1, Petrukhin V.A.1, Budykina T.S.1, Panov A.E.1
-
Affiliations:
- Moscow Regional Scientific Research Institute for Obstetrics and Gynecology
- Issue: Vol 48, No 7 (2020)
- Pages: 469-475
- Section: ARTICLES
- URL: https://almclinmed.ru/jour/article/view/1404
- DOI: https://doi.org/10.18786/2072-0505-2020-48-069
- ID: 1404
Cite item
Full Text
Abstract
Background: High-performance parallel next-generation sequencing (NGS) allows for identification of various maturity-onset diabetes of the young (MODY) subtypes also during pregnancy. As this method is expensive and time-consuming, it has proposed to use various predictors for the diagnosis of mutation in the hexokinase (GCK)/MODY2 gene, helping to select the patients for subsequent molecular genetic testing. Hyperglycemia due to MODY2 is commonly newly diagnosed during pregnancy; therefore, there is a search for factors specific to this mutation in pregnant women.
Aim: To evaluate blood glucose variability in pregnant women with newly diagnosed hyperglycemia at early gestation and to determine the threshold value of the glycemic variability coefficient for pregnant women with a mutation in the GCK/MODY2 gene.
Materials and methods: This observational single center study included 41 pregnant women with newly diagnosed early hyperglycemia (not meeting the criteria for manifest diabetes mellitus). Molecular genetic testing was performed in all of them. According to its results, they were retrospectively categorized into two groups: with early gestational diabetes mellitus (GDM, no mutations) and with hyperglycemia related to a mutation in the GCK/MODY2 gene. A comparative analysis of glycemic variability in the two groups was performed. Sensitivity and specificity of the cutoff value for the coefficient of variability as a diagnostic marker of MODY2 were also calculated.
Results: The pregnant women with GDM had significantly higher age and body mass index (BMI) than those with MODY2 (p<0.05). There were significant differences in venous fasting plasma glucose and glycated hemoglobin, with these parameters being higher in the pregnant women with MODY2 (p<0.05). In the patients with a mutation in the GCK gene, hyperglycemia was diagnosed earlier and insulin therapy was started earlier during pregnancy than in those with GDM (p<0.05). The ROC analysis of the diagnostic accuracy of the variability coefficient showed that at the threshold CV (coefficient of variation) value of 20.8, the area under the curve was 0.742 (95% confidence intervals 0.597 to 0.888; p<0.005), with the sensitivity of 65% and the specificity of 65.4%.
Conclusion: The calculated sensitivity of 65% and specificity of 65.4% for the CV of 20.8 do not allow for its use as an independent selection criterion for subsequent confirmation of MODY2. However, its combination with the A.J. Chakera criteria (BMI<25 kg/m2 and fasting glucose≥5.5 mmol with 68% sensitivity and 96% specificity) allows to clarify the category of pregnant women with newly detected early hyperglycemia, to whom the search for mutations in the GCK gene should be recommended.
About the authors
M. A. Plekhanova
Moscow Regional Scientific Research Institute for Obstetrics and Gynecology
Author for correspondence.
Email: margarita_kr@list.ru
ORCID iD: 0000-0002-5322-1021
Margarita A. Plekhanova – MD, Endocrinologist, Outpatient Department
22a Pokrovka ul., Moscow, 101000
РоссияF. F. Burumkulova
Moscow Regional Scientific Research Institute for Obstetrics and Gynecology
Email: fatima-burumkulova@yandex.ru
ORCID iD: 0000-0001-9943-0964
Fatima F. Burumkulova – MD, PhD, Leading Research Fellow
22a Pokrovka ul., Moscow, 101000
РоссияV. A. Petrukhin
Moscow Regional Scientific Research Institute for Obstetrics and Gynecology
Email: petruhin271058@mail.ru
ORCID iD: 0000-0003-0460-3047
Vasily A. Petrukhin – MD, PhD, Professor, Director
22a Pokrovka ul., Moscow, 101000
РоссияT. S. Budykina
Moscow Regional Scientific Research Institute for Obstetrics and Gynecology
Email: budyt@mail.ru
ORCID iD: 0000-0001-9873-2354
Tatiana S. Budykina – MD, PhD, Head of Clinical Diagnostic Laboratory
22a Pokrovka ul., Moscow, 101000
РоссияA. E. Panov
Moscow Regional Scientific Research Institute for Obstetrics and Gynecology
Email: drpanov82@gmail.com
ORCID iD: 0000-0002-9362-0852
Anton E. Panov – MD, Research Fellow
22a Pokrovka ul., Moscow, 101000
РоссияReferences
- Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH. Glucose variability; does it matter? Endocr Rev. 2010;31(2):171–82. doi: 10.1210/er.2009-0021.
- Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, Bosi E, Buckingham BA, Cefalu WT, Close KL, Cobelli C, Dassau E, DeVries JH, Donaghue KC, Dovc K, Doyle FJ 3rd, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch IB, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Levine B, Mayorov A, Mathieu C, Murphy HR, Nimri R, Nørgaard K, Parkin CG, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer SA, Phillip M. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593–603. doi: 10.2337/dci19-0028.
- Feig DS, Donovan LE, Corcoy R, Murphy KE, Amiel SA, Hunt KF, Asztalos E, Barrett JFR, Sanchez JJ, de Leiva A, Hod M, Jovanovic L, Keely E, McManus R, Hutton EK, Meek CL, Stewart ZA, Wysocki T, O'Brien R, Ruedy K, Kollman C, Tomlinson G, Murphy HR; CONCEPTT Collaborative Group. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet. 2017;390(10110):2347–59. doi: 10.1016/S0140-6736(17)32400-5.
- Chakera AJ, Steele AM, Gloyn AL, Shepherd MH, Shields B, Ellard S, Hattersley AT. Recognition and Management of Individuals With Hyperglycemia Because of a Heterozygous Glucokinase Mutation. Diabetes Care. 2015;38(7):1383–92. doi: 10.2337/dc14-2769.
- Baz B, Riveline JP, Gautier JF. Endocrinology of pregnancy: Gestational diabetes mellitus: definition, aetiological and clinical aspects. Eur J Endocrinol. 2016;174(2):R43–51. doi: 10.1530/EJE15-0378.
- Doddabelavangala Mruthyunjaya M, Chapla A, Hesarghatta Shyamasunder A, Varghese D, Varshney M, Paul J, Inbakumari M, Christina F, Varghese RT, Kuruvilla KA, V Paul T, Jose R, Regi A, Lionel J, Jeyaseelan L, Mathew J, Thomas N. Comprehensive maturity onset diabetes of the young (MODY) gene screening in pregnant women with diabetes in India. PLoS One. 2017;12(1):e0168656. doi: 10.1371/journal.pone.0168656.
- Okruszko A, Kinalski M, Kuźmicki M, Mirończuk K, Wawrusiewicz-Kurylonek N, Kinalska I, Kretowski A. Mutacje genu glukokinazy w cukrzycy ciezarnych w populacji polskiej. Prognozowanie ryzyka rozwoju cukrzycy po ciazy [Glucokinase gene mutations in gestational diabetes in Polish population. Prediction of diabetes mellitus development after delivery]. Przegl Lek. 2007;64(6):401–5. Polish.
- Ellard S, Beards F, Allen LI, Shepherd M, Ballantyne E, Harvey R, Hattersley AT. A high prevalence of glucokinase mutations in gestational diabetic subjects selected by clinical criteria. Diabetologia. 2000;43(2):250–3. doi: 10.1007/s001250050038.
- Siddiqui S, Waghdhare S, Gopi S, Bhargava A, Panda M, Radha V, Mohan V, Dubey S, Jha S. GCK gene screening and association of GCK variants with gestational diabetes in North Indian population. Clin Med Insights Endocrinol Diabetes. 2018;11:1179551418806896. doi: 10.1177/1179551418806896.
- Chakera AJ, Spyer G, Vincent N, Ellard S, Hattersley AT, Dunne FP. The 0.1% of the population with glucokinase monogenic diabetes can be recognized by clinical characteristics in pregnancy: the Atlantic Diabetes in Pregnancy cohort. Diabetes Care. 2014;37(5):1230–6. doi: 10.2337/dc13-2248.
- Stride A, Vaxillaire M, Tuomi T, Barbetti F, Njølstad PR, Hansen T, Costa A, Conget I, Pedersen O, Søvik O, Lorini R, Groop L, Froguel P, Hattersley AT. The genetic abnormality in the beta cell determines the response to an oral glucose load. Diabetologia. 2002;45(3):427–35. doi: 10.1007/s00125-001-0770-9.
- Lun FM, Tsui NB, Chan KC, Leung TY, Lau TK, Charoenkwan P, Chow KC, Lo WY, Wanapirak C, Sanguansermsri T, Cantor CR, Chiu RW, Lo YM. Noninvasive prenatal diagnosis of monogenic diseases by digital size selection and relative mutation dosage on DNA in maternal plasma. Proc Natl Acad Sci U S A. 2008;105(50):19920–5. doi: 10.1073/pnas.0810373105.
- Дедов ИИ, Краснопольский ВИ, Сухих ГТ. Российский национальный консенсус гестационный сахарный диабет: диагностика, лечение, послеродовое наблюдение? Сахарный диабет. 2012;15(4):4–10. doi: 10.14341/2072-0351-5531.
- Nielsen LR, Pedersen-Bjergaard U, Thorsteinsson B, Johansen M, Damm P, Mathiesen ER. Hypoglycemia in pregnant women with type 1 diabetes: predictors and role of metabolic control. Diabetes Care. 2008;31(1):9–14. doi: 10.2337/dc07-1066.
- Colom C, Corcoy R. Maturity onset diabetes of the young and pregnancy. Best Pract Res Clin Endocrinol Metab. 2010;24(4):605–15. doi: 10.1016/j.beem.2010.05.008.
- Spyer G, Hattersley AT, Sykes JE, Sturley RH, MacLeod KM. Influence of maternal and fetal glucokinase mutations in gestational diabetes. Am J Obstet Gynecol. 2001;185(1):240–1. doi: 10.1067/mob.2001.113127.
- Sénat MV, Affres H, Letourneau A, Coustols-Valat M, Cazaubiel M, Legardeur H, Jacquier JF, Bourcigaux N, Simon E, Rod A, Héron I, Castera V, Sentilhes L, Bretelle F, Rolland C, Morin M, Deruelle P, De Carne C, Maillot F, Beucher G, Verspyck E, Desbriere R, Laboureau S, Mitanchez D, Bouyer J; Groupe de Recherche en Obstétrique et Gynécologie (GROG). Effect of glyburide vs subcutaneous insulin on perinatal complications among women with gestational diabetes: A randomized clinical trial. JAMA. 2018;319(17): 1773–80. doi: 10.1001/jama.2018.4072.
- Velho G, Hattersley AT, Froguel P. Maternal diabetes alters birth weight in glucokinase-deficient (MODY2) kindred but has no influence on adult weight, height, insulin secretion or insulin sensitivity. Diabetologia. 2000;43(8):1060–3. doi: 10.1007/s001250051490.
Supplementary files
